12 rezultatus
BACKGROUND OF THE INVENTION
The present invention relates to certain novel osmium-carbohydrate complexes.
Osmium has been shown to be effective in the treatment of rheumatoid arthritis [I. Boussina, et al, Scand. J. Rheumatology, 5,53 (1976)]. Osmium tetroxide (OsO.sub.4) has had limited use in the
FIELD OF THE INVENTION
The present disclosure relates to: (a) processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-- trifluoroethyl)pyrrolidine-1-carboxamide (referred to herein as "Compound 1"), (b) intermediates used in the preparation of
BACKGROUND OF THE INVENTION
This invention relates to a process and medium for culturing ant venom gland cells. More particularly, this invention relates to a process, cell culture and cell culture medium for in vitro culture of cells of the venom gland of the ant Pseudomyrmex triplarinus.
The cells
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is in the field of medicinal chemistry and is directed to carbocyclic hydrazino compounds and their use as inhibitors of copper-containing amine oxidases (E.C. 1.4.3.6) and enzymes of significant identity thereto. The
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is in the field of medicinal chemistry and is directed to hydrazino compounds and their use as inhibitors of copper-containing amine oxidases (E.C. 1.4.3.6) and enzymes of significant identity thereto. The compounds of the
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention is principally concerned with the use of sulfamic acid derivatives in the treatment of mammals in several therapeutic areas. More particularly the invention is concerned with the pharmaceutical use of compounds and
BACKGROUND OF THE INVENTION
1. Field of Invention
The present invention is principally concerned with the use of sulfamic acid derivatives in the treatment of mammals in several therapeutic areas. More particularly the invention is concerned with the pharmaceutical use of compounds and
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
BACKGROUND OF THE INVENTION
Type 2 diabetes, also referred to as non-insulin dependent diabetes mellitus (NIDDM), afflicts between 80 and 90% of all diabetic patients in developed countries. In the United States alone, approximately 15 million people, and more than 100 million worldwide, are
This application is a 371 of PCT/JP03/11835 filed Sep. 17, 2003 which claims priority to JAPAN 2002-272079 filed Sep. 18, 2002.
TECHNICAL FIELD
The present invention relates to crystals of (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carb-